Literature DB >> 15670731

Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.

Csilla Ozvegy-Laczka1, Gabriella Köblös, Balázs Sarkadi, András Váradi.   

Abstract

The human ABCG2 protein is an ATP binding cassette half-transporter, which protects our cells and tissues against various xenobiotics, while overexpression of ABCG2 in tumor cells confers multidrug resistance. It has been documented that single amino acid changes at position 482 resulted in altered drug resistance and transport capacity. In this study, we have generated nine Arg-482 mutants (G, I, M, S, T, D, N, K, Y) of ABCG2, and expressed them in insect cells. All ABCG2 variants showed cell surface expression and, in isolated membranes, an ABCG2-specific ATPase activity. When methotrexate accumulation was measured in inside-out membrane vesicles, this transport was supported only by the wild-type ABCG2. In intact cells, mitoxantrone was transported by all ABCG2 variants, except by R482K. Rhodamine 123 was extruded by most of the mutants, except by R482K, Y and by wild-type ABCG2. Hoechst 33342 was pumped out from cells expressing the wild-type and all Arg-482 variants, but not from those expressing R482K and Y. Our study demonstrates that the substrate specificity of the Arg (wild-type) form is unique and that amino acid replacements at position 482 induce major alterations in both the transport activity and substrate specificity of this protein.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15670731     DOI: 10.1016/j.bbamem.2004.11.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  29 in total

Review 1.  Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design.

Authors:  Toshihisa Ishikawa; Ai Tamura; Hikaru Saito; Kanako Wakabayashi; Hiroshi Nakagawa
Journal:  Naturwissenschaften       Date:  2005-10

2.  Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.

Authors:  Yan-Jun Mi; Yong-Ju Liang; Hong-Bing Huang; Hong-Yun Zhao; Chung-Pu Wu; Fang Wang; Li-Yang Tao; Chuan-Zhao Zhang; Chun-Ling Dai; Amit K Tiwari; Xiao-Xu Ma; Kenneth Kin Wah To; Suresh V Ambudkar; Zhe-Sheng Chen; Li-Wu Fu
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

3.  The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding.

Authors:  Karin F K Ejendal; Ndeye Khady Diop; Linda C Schweiger; Christine A Hrycyna
Journal:  Protein Sci       Date:  2006-07       Impact factor: 6.725

4.  Fluorescence resonance energy transfer (FRET) analysis demonstrates dimer/oligomer formation of the human breast cancer resistance protein (BCRP/ABCG2) in intact cells.

Authors:  Zhanglin Ni; Michelle E Mark; Xiaokun Cai; Qingcheng Mao
Journal:  Int J Biochem Mol Biol       Date:  2010

Review 5.  Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).

Authors:  Zhanglin Ni; Zsolt Bikadi; Mark F Rosenberg; Qingcheng Mao
Journal:  Curr Drug Metab       Date:  2010-09       Impact factor: 3.731

6.  The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone.

Authors:  Mark F Rosenberg; Zsolt Bikadi; Janice Chan; Xiaoping Liu; Zhanglin Ni; Xiaokun Cai; Robert C Ford; Qingcheng Mao
Journal:  Structure       Date:  2010-03-14       Impact factor: 5.006

7.  Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.

Authors:  Chun-ling Dai; Amit K Tiwari; Chung-Pu Wu; Xiao-Dong Su; Si-Rong Wang; Dong-geng Liu; Charles R Ashby; Yan Huang; Robert W Robey; Yong-ju Liang; Li-ming Chen; Cheng-Jun Shi; Suresh V Ambudkar; Zhe-Sheng Chen; Li-wu Fu
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

8.  Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.

Authors:  D M Collins; J Crown; N O'Donovan; A Devery; F O'Sullivan; L O'Driscoll; M Clynes; R O'Connor
Journal:  Invest New Drugs       Date:  2009-06-05       Impact factor: 3.850

9.  Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters.

Authors:  J Jacob Strouse; Irena Ivnitski-Steele; Anna Waller; Susan M Young; Dominique Perez; Annette M Evangelisti; Oleg Ursu; Cristian G Bologa; Mark B Carter; Virginia M Salas; George Tegos; Richard S Larson; Tudor I Oprea; Bruce S Edwards; Larry A Sklar
Journal:  Anal Biochem       Date:  2013-03-05       Impact factor: 3.365

10.  Arginine 383 is a crucial residue in ABCG2 biogenesis.

Authors:  Orsolya Polgar; Lilangi S Ediriwickrema; Robert W Robey; Ajay Sharma; Ramanujan S Hegde; Yongfu Li; Di Xia; Yvona Ward; Michael Dean; Csilla Ozvegy-Laczka; Balazs Sarkadi; Susan E Bates
Journal:  Biochim Biophys Acta       Date:  2009-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.